Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 15, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 ordinary shares.
- Purchase Price: 1,313.04 pence per share.
- Total Treasury Shares Held: 315,739,158 shares (representing 5.53% of total voting rights).
- Shares in Issue: 5,704,951,850 shares (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the June 15, 2007 purchase. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure that the announcement does not constitute an offer to purchase securities. The transaction was executed in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,704,951,850) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count of 315,739,158, which equates to 5.53% of total voting rights.
- Note that this filing is a notification of a specific share buyback event and does not contain quarterly or annual financial results.